EMA approves AZ's Imfinzi for Stage III NSCLC
24 September 2018 16:10 BST European Commission approves Imfinzi for locally-advanced, unresectable NSCLC Phase III PACIFIC trial demonstrated compelling overall survivalbenefit and progression-free survival of more than 11 months Imfinzi is the only immunotherapy medicine approved forthe treatment of locally-advanced, unresectable NSCLC AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the European Commission has granted marketing authorisation for Imfinzi (durvalumab) as monotherapy for the treatment of locally-